Alaya.bio Acquires Key Assets from Ixaka France to Address Challenges in Development and Commercialisation of Autologous Cell Therapies.

MANews-(C)2009-2023

Massachusetts, US-based gene delivery biotech company Alaya.bio has acquired all assets previously owned by preclinical-stage immunotherapy biotech company Ixaka France, a specialising in in vivo CAR T-cell therapy to accelerate progress of novel in vivo CAR-T immunotherapy platform, the company said.

Terms of the transaction were not disclosed.

Alaya.bio intends to leverage its combined assets to simplify the way CAR-T cell therapies are being developed, manufactured and administered.

This acquisition accelerates Alaya.bio's programmes, providing data showing preclinical proof of concept of the anti-tumoral efficacy of in vivo engineered CAR T cells in immunocompetent mouse models.

It includes a broad and robust patent portfolio...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT